In the context of gut peptides, current anti‐obesity medications primarily involve drugs that target the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and gastric inhibitory polypeptide (GIP).25, 26. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.